8-K: Beyond Air Gets Nasdaq Listing Extension

Beyond Air has been granted a conditional extension by the Nasdaq Hearings Panel to regain compliance with the bid price rule by July 31, 2026, with a potential reverse stock split on the horizon.

Summary

• Beyond Air, Inc. received a decision from the Nasdaq Hearings Panel on May 28, 2026, granting it continued listing on the Nasdaq Stock Market.
• The company must demonstrate compliance with the Bid Price Rule (Nasdaq Listing Rule 5550(a)(2)) by July 31, 2026.
• Following the decision, the company will be subject to a Discretionary Panel Monitor for one year after regaining compliance.
• Failure to meet listing standards during the monitoring period could result in a prompt delisting determination.
• A press release announcing the Panel's decision was issued on June 1, 2026.
• Shareholders will vote on a proposal for a reverse stock split at a special meeting on June 18, 2026, which is intended to help regain compliance with the bid price requirement.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as the company has secured a crucial extension to remain listed on Nasdaq, providing time to address compliance issues. However, the conditional nature of the listing and the reliance on a reverse stock split introduce ongoing uncertainty.

Positives

• The Nasdaq Hearings Panel has granted Beyond Air a conditional extension to continue listing on the Nasdaq Stock Market.
• The company is fully compliant with all other continued listing requirements.
• The company has until July 31, 2026, to regain compliance with the Bid Price Rule.
• The CEO expressed appreciation for the Panel's review and support of their compliance plan.
• The decision provides time to complete necessary steps to regain compliance while focusing on commercial execution and platform development.

Negatives

• The company must regain compliance with the Bid Price Rule by July 31, 2026, to avoid potential delisting.
• Failure to meet listing standards during the one-year monitoring period could lead to immediate delisting without the option to present a new compliance plan.
• The effectiveness of a potential reverse stock split in increasing or maintaining the market price of the company's common stock is uncertain.

Risks

• Risk of failing to regain compliance with the Bid Price Rule by July 31, 2026.
• Risk of failing to meet any listing standard during the one-year Discretionary Panel Monitor period.
• Potential for delisting if compliance is not maintained.
• Uncertainty regarding the approval and effectiveness of a potential reverse stock split.
• Risks associated with executing the commercial strategy and achieving market adoption of products.
• Risks related to obtaining additional financing.

Future Outlook

The company is focused on advancing its commercial execution and progressing its next-generation portable nitric oxide platform. Shareholders will vote on a reverse stock split proposal on June 18, 2026, which is expected to be implemented if approved to facilitate regaining compliance with the Nasdaq bid price requirement. The company aims to regain compliance with the Bid Price Rule by July 31, 2026.

Management Comments

• "We appreciate the Panels thoughtful review and support of our compliance plan," said Robert Goodman, Chief Executive Officer of Beyond Air.
• "This decision provides us with the time needed to complete the steps necessary to regain compliance while we remain focused on advancing our commercial execution and progressing our next-generation portable nitric oxide platform."

Industry Context

StockSavvy.ai notes that maintaining a listing on major exchanges like Nasdaq is critical for companies, especially those in the commercial-stage medical device and biopharmaceutical sector, to access capital and maintain investor confidence. The focus on a bid price requirement is a common challenge for smaller or growth-stage companies, often addressed through corporate actions like reverse stock splits.

Corporate Governance

Stakeholder Impact

• Shareholders: The potential reverse stock split could impact share count and per-share value, though it aims to maintain Nasdaq listing. Continued listing is positive for investor confidence.
• Creditors: Maintaining Nasdaq listing is generally positive for a company's financial stability and ability to access future financing.
• Employees: Continued listing provides job security and stability.
• Customers: Continued operation and listing stability are important for customer confidence in the company's products and services.

Next Steps

• Demonstrate compliance with the Nasdaq Bid Price Rule on or before July 31, 2026.
• Hold a special meeting of stockholders on June 18, 2026, to vote on a reverse stock split proposal.
• Implement a reverse stock split if approved by stockholders.
• Undergo a one-year Discretionary Panel Monitor period after regaining compliance.

Key Dates

Recommendation

The company has secured a critical extension to remain listed on Nasdaq, which is a positive development. However, the requirement to regain compliance with the bid price rule by July 31, 2026, and the potential need for a reverse stock split introduce significant uncertainty. While the immediate risk of delisting has been mitigated, the path to sustained compliance and growth remains challenging. Investors should hold to see the outcome of the reverse stock split vote and the company's ability to meet the July deadline.

Keywords

Nasdaq Listing, Bid Price Rule, Beyond Air, Compliance Plan, Reverse Stock Split, Delisting, XAIR, Medical Device